WAYNE, Pa., March 09, 2021 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) today announced that, globally, 250,000 patients have been treated with the UroLift ® System, a proven, minimally ...

New Delhi, Nov 09, 2022: Teleflex has announced the commercial launch of the UroLift System in India for treating benign prostatic hyperplasia (BPH), or enlarged prostate. The UroLift System is a ...

This is an archived article and the information in the article may be outdated. Please look at the time stamp on the story to see when it was last updated. Sponsored content: Enlarged prostate affects ...

Teleflex announces favorable results for UroLift™ in treating BPH, showing higher patient satisfaction and better early recovery compared to Rezūm. Teleflex Incorporated announced new results from the ...

Teleflex Incorporated TFX has been witnessing gradual rebound in revenues, driven by stable performance across it operating segments and geographies. The stock currently carries a Zacks Rank #3 (Hold) ...

MINNEAPOLIS (WCCO)-- Experts say as men age, their prostate gland can become enlarged and affects how often they have to go to the bathroom, among other disruptions. Now, there's a newer in-office ...

Minimally invasive surgery to reduce the incidence of erectile dysfunction and other nasty side effects of procedures to treat an enlarged prostate is now more accessible due to Medicare reimbursement ...

The committee concluded that UroLift is clinically effective, with sustained relief of lower urinary tract symptoms up to 5 years after treatment. It is implanted using a minimally invasive procedure.

UroLift is a minimally invasive treatment option for benign prostatic hyperplasia (BPH), also called enlarged prostate. Medicare covers the UroLift procedure when a doctor deems it medically necessary ...

WAYNE, PA — Teleflex Incorporated (NYSE: TFX) has unveiled groundbreaking results from the CLEAR study, the first head-to-head randomized controlled trial comparing the UroLift™ System with Rezūm™ ...